Efficacy and safety of olanexidine gluconate for skin disinfection of blood culture collectio

Phase 2

Recruiting

• Conditions: Infections; Infections, Sepsis, Bacteremia

• Registration Number: JPRN-jRCTs061220073
• Lead Sponsor: Ota Kohei

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-12-05
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 215

Inclusion Criteria

1. over 18 years
2. Patients from whom blood culture was collected in the emergency department or the intensive care unit
3. Provision of written informed consent from patients or their surrogate

Exclusion Criteria

1. History of allergy or contact dermatitis caused by 1.5% oranexidine (for those who have already been enrolled in this study, including those who have been found to have adverse events in this study for which a causal relationship with 1.5% oranexidine cannot be denied.)
2. Patients with systemic skin diseases
3. Patients with wound or skin ulcer at the puncture site
4. Patients whose puncture site is contaminated with feces, urine, or sludge, and who require procedures other than disinfection such as wiping.
5. Patients who have received antimicrobial agents with antimicrobial activity against contaminating bacteria.

Study & Design

• Study Type: Interventional
• Study Design: Not specified